New combo aims to beat hairy cell leukemia with fewer side effects
NCT ID NCT05388123
First seen May 12, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tested a new treatment for hairy cell leukemia using two drugs: vemurafenib (a pill) and rituximab (an IV infusion). The goal was to see if this combination works better and causes fewer side effects than standard chemotherapy. The study included 15 adults with hairy cell leukemia who had not been treated before or whose cancer had returned after prior therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scripps Cancer Center
La Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.